Clinical Characteristics and Spermatogenesis in Patients with Congenital Hypogonadotropic Hypogonadism Caused by FGFR1 Mutations

Table 2

Comparison of clinical characteristics between the FGFR1 gene group and the mutation-negative group at baseline.

Groups	FGFR1 mutation (n = 14)	Mutation-negative (n = 25)
Kallmann/nCHH (n/n)	8/6	20/5	0.156
Gonadotropin/GnRH pulsatile (n/n)	10/4	12/13	0.193
Number of testosterone users before sperm promoting therapy (n, %)	11, 78.57%	12, 480.00%	0.093
Previous testosterone treatment course (years)	1 (1–2) (n = 11)	1 (0.5–4) (n = 12)	0.441
Cryptorchidism or history of cryptorchidism (n, %)	7, 50.0% (Unilateral/Bilateral = 3/4)	3, 12.0% (Unilateral/Bilateral = 1/2)	0.019
Age of start for spermatogenic treatment (years)	20.00 (18.75–24.75)	24.12 ± 5.75	0.297
Baseline testicular size (mL)	1.6 (0.5–2.0)	2.0 (1.75–4)	0.033
Baseline LH (IU/L)	0.20 (0.10–0.70)	0.35 (0.20–0.72)	0.318
Baseline FSH (IU/L)	1.01 ± 0.85	0.60 (0.22–1.58)	0.714
Baseline testosterone (ng/dL)	24.1 (18.58–37.25)	32.70 (20.65–46.5)	0.198
LH 60 min after triptorelin stimulating test (IU/L)	2.3 (1.16–5.68)	1.75 (0.77–5.78)	0.529
Nonreproductive phenotype	Obesity (n = 2)	Obesity (n = 3); diabetes (n = 1); solitary kidney (n = 1); strabismus (n = 1); unilateral ptosis (n = 1); multiple facial nevi (n = 1);